Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$1.9 million.

  • Taysha Gene Therapies' Change in Account Payables rose 4847.92% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $469000.0, marking a year-over-year increase of 11772.49%. This contributed to the annual value of -$2.9 million for FY2024, which is 2723.31% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Change in Account Payables is -$1.9 million, which was up 4847.92% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Change in Account Payables peaked at $4.0 million during Q1 2024, and registered a low of -$9.4 million during Q3 2022.
  • For the 4-year period, Taysha Gene Therapies' Change in Account Payables averaged around -$736400.0, with its median value being -$1.2 million (2023).
  • The largest annual percentage gain for Taysha Gene Therapies' Change in Account Payables in the last 5 years was 100863.51% (2024), contrasted with its biggest fall of 19155.33% (2024).
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Change in Account Payables stood at -$4.6 million in 2022, then skyrocketed by 73.19% to -$1.2 million in 2023, then fell by 22.28% to -$1.5 million in 2024, then fell by 29.52% to -$1.9 million in 2025.
  • Its Change in Account Payables stands at -$1.9 million for Q3 2025, versus $3.0 million for Q2 2025 and $923000.0 for Q1 2025.